What we are studying
Cynapsus, the study sponsor, is developing the study drug called APL-130277, a fast-acting thin film formulation of apomorphine that is placed under the tongue and is intended to be an alternative to the injectable form of apomorphine. This study is designed to determine the effectiveness, safety, and tolerability of multiple treatments of APL-130277 in patients with Parkinson’s disease who experience OFF episodes. In this study all subjects will receive APL-130277.
There will be compensation for completed visits.